Table 1—

Demographic and clinical characteristics of different courses of PTDM

P-PTDML-PTDMT-PTDMN-PTDM7
n (% female)18 (61.1)9 (28.6)12 (33.3)38 (26.3)
Age (years)45.3 ± 10.134.7 ± 10.631.3 ± 9.734.2 ± 9.2
Family history of diabetes*8 (44.4)1 (11.1)3 (25)8 (21.1)
Duration of dialysis (months)13.2 ± 16.17.6 ± 16.4 ± 8.617.7 ± 21.2
HCV infection2 (11.1)0 (0)0 (0)1 (2.6)
Donor type (LURDs)8 (66.7)2 (22.2)6 (50)8 (21.1)
Calcineurin inhibitor
    CsA11 (61.1)7 (77.8)8 (66.7)32 (84.2)
    Tacrolimus7 (38.9)2 (22.2)4 (33.3)6 (15.8)
MMF10 (55.6)5 (55.6)7 (58.3)16 (42.1)
Acute rejection4 (22.2)1 (11.1)8 (66.7)0 (0)
BMI (kg/m2)
    Before transplantation22.8 ± 3.222.9 ± 3.719.5 ± 2.321.0 ± 2.3
    1 year after transplantation24.0 ± 3.324.0 ± 3.120.0 ± 2.321.6 ± 2.7
FPG (mmol/l)
    Before transplantation4.8 ± 0.44.4 ± 0.74.7 ± 0.44.7 ± 0.4
    1 year after transplantation6.5 ± 1.15.7 ± 0.65.2 ± 0.65.3 ± 0.6
Total cholesterol (mmol/l)
    Before transplantation4.4 ± 0.94.2 ± 1.04.2 ± 0.73.9 ± 0.9
    1 year after transplantation6.4 ± 1.06.2 ± 0.85.7 ± 1.05.6 ± 1.1
Triglycerides (mmol/l)
    Before transplantation2.2 ± 1.22.6 ± 1.11.9 ± 0.81.8 ± 1.1
    1 year after transplantation2.2 ± 0.72.8 ± 1.22.3 ± 2.72.1 ± 0.8
  • Data are expressed as n (%) or means ± SD.

  • *

    * Family history of diabetes in a first-degree relative.

  • P < 0.05,

  • P < 0.001 vs. N-PTDM7. HCV, hepatitis C virus; LURD, living unrelated donor.